➤ Affect people of all ages, genders, and occupations
➤ The leading cause of disability
➤ The second leading cause of death
~1 billion people suffer from neurological disorders
~ 7 million people are dying from neurological disorders
Neurological Disorders
Elena Molokanova, PhD
Elena Molokanova, PhD
- CEO
- MS in Physics
- PhD in Biological Sciences
Berkeley
Elena Molokanova, PhD
Alex Savtchenko, PhD
- CSO
- MS in Physics and Chemistry
- PhD in Biological Sciences
Stanford
Academic Alliances
Albert La Spada, MD, PhD
Albert La Spada, MD, PhD
Distinguished Professor and Vice Chair, University of California - Irvine
Director, UCI Institute for Neurotherapeutics
Expertise: neurodegenerative disorders
Byungkook Lim, PhD
Byungkook Lim, PhD
Associate Professor
Division of Biological sciences, University of California-San Diego
Expertise: Drug addiction, depression
Alysson Muotri, PhD
Alysson Muotri, PhD
Professor
Departement of Pediatrics, University of California-San Diego
Expertise: Autistic spectrum disorders
Nana Voitenko, PhD
Nana Voitenko, PhD
Departement of Sensory Signaling
Bogomoletz Institute of Physiology, Kyiv, Ukraine
Expertise: Pain, traumatic brain injury
Oliver Hardt, PhD
Oliver Hardt, PhD
Associate Professor
Departement of Psychology, McGill University, Canada
Expertise: Memory
The National Institute on Drug Abuse
SBIR Phase I
“Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for treatment of opioid use disorder”
The National Institute on Drug Abuse
The National Institute on Drug Abuse
The National Institute of Neurological Disorders and Stroke
SBIR Phase I
“Pre-clinical evaluation of a rationally designed nanotherapeutic for Huntington's disease”
The National Institute on Aging
SBIR Phase I
“Alzheimer's disease and novel nanotherapeutics exclusively targeting extrasynaptic NMDA receptors”
The National Institute on Drug Abuse
Health
Glutamate inside the synapses supports communications between neurons.
Glutamatergic synaptic NMDA receptors are involved in physiological processes, such as breathing, talking, walking, learning, thinking...
Injury/Disorder
Injury may leads to glutamate being present
outside synapses.
Extrasynaptic NMDA receptors are activated during pathological events, and implicated in mediating glutamatergic excitotoxicity
Strategy
Strategy
Strategy
Alzheimer’s Disease
Alzheimer’s Disease
During AD, damaged neurons are “spilling” glutamate outside synapses, which leads to activation of extrasynaptic NMDA receptors, the loss of synapses, and neuronal death.
By blocking extrasynaptic NMDARs, AuM will:
• protect neurons from glutamatergic excitotoxicity;
• exceed therapeutic effects of memantine (Namenda);
• be beneficial from the very early stages of AD.
Traumatic Brain Injury
Traumatic Brain Injury
During TBI, a glutamate “spill” radiates out from the area of original injury, and kills neurons in nearby areas via overactivation extrasynaptic NMDA receptors.
AuM can limit, prevent, and even reverse the secondary injury by blocking this pathway and stopping the vicious circle of amplifying glutamate-triggered destructive events.
Huntington’s Disease
Huntington’s Disease
Well-established downstream pathways in HD include dysregulation of extrasynaptic NMDA receptors, leading to excitotoxicity and activation of cell-death pathways.
AuM can target these pathways and provide neuroprotection, which can slow the disease progression and, possibly, even reverse its course.
Opioid Use Disorder
Opioid Addiction Disorder
Disruption of glutamatergic pathways has been implicated in drug-dependent excitotoxicity, drug seeking and reinstatement, as well as reward and reinforcement.
By exclusively blocking extrasynaptic NMDA receptors, AuM may affect different stages of OUD: withdrawal, development of opioid dependence, and relapse.
GALLERY
NeurANO Bioscience
NeurANO Bioscience
NeurANO Bioscience
NeurANO Bioscience
NeurANO Bioscience
NeurANO Bioscience
NeurANO Bioscience
NeurANO Bioscience
NeurANO Bioscience
NeurANO Bioscience
News
June 2022
NeurANO Bioscience was selected to present at the BIO2022 start-up stadium on June 14, 2022.
May 2022
NeurANO Bioscience was selected for a competitive FAST Advisory program by the California LifeScience (CLS) organization.
September 2021
NeurANO Bioscience was awarded the SBIR Phase I grant “Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for treatment of opioid use disorder” from the National Institute on Aging.
August 2021
NeurANO Bioscience was awarded SBIR Phase I grant “Preclinical evaluation of a rationally designed nanotherapeutic for Huntington's disease” from the National Institute on Neurological disorders and stroke.
October 2019
NeurANO Bioscience presented the Proof-of-Concept data for the project "Exclusive targeting of extrasynaptic NMDA receptors improves mice cognitive function after mild traumatic brain injury" ( https://www.abstractsonline.com/pp8/#!/7883/presentation/68229) and " Exclusive antagonists of extrasynaptic NMDA receptors for autism (https://www.abstractsonline.com/pp8/#!/7883/presentation/47176)
August 2019
NeurANO Bioscience was awarded SBIR Phase I grant “Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for treatment of opioid use disorder” from the National Institute on Drug Abuse.